Part D 2007 Negotiations: Will Rebate Emphasis Change To Pricing Demands?
The major Part D plan sponsors may have favored receiving drug rebates over drug price discounts in negotiations with pharmaceutical manufacturers for the 2006 benefit year, based on a recently released 1analysis by the Kaiser Family Foundation
You may also be interested in...
Too many drugs will be subject to the maximum copay on Part D formularies if CMS allows plans to place all therapies with negotiated prices greater than $500 per month on the specialty tier, according to the Biotechnology Industry Organization
Pfizer appears to have taken an all-or-nothing approach to negotiating formulary positioning for its products in Medicare Part D prescription drug plans, according to an analysis by "The Pink Sheet" of plan formularies
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011